Overview

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

Status:
Completed
Trial end date:
2015-06-11
Target enrollment:
Participant gender:
Summary
This study is to characterize the pharmacokinetics and to evaluate the safety as well as tolerability of LY03003 following multiple escalating intramuscular injections
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Collaborator:
Beijing Bozhiyin T&S Co., Ltd.
Treatments:
Rotigotine